Navigation Links
Mylan's Matrix Receives Approval for Generic Version of Protonix® Delayed-release Tablets
Date:1/24/2011

PITTSBURGH, Jan. 24, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Matrix Laboratories Limited has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Pantoprazole Sodium Delayed-release (DR) Tablets USP, 20 mg (base) and 40 mg (base), the generic version of Wyeth's Protonix® DR Tablets, a treatment for the irritation of the esophagus caused by gastroesophageal reflux disease (GERD).

Pantoprazole Sodium DR Tablets had U.S. sales of approximately $1.7 billion for the 12 months ending Sept. 30, 2010, according to IMS Health. Mylan Pharmaceuticals Inc. is shipping this product immediately.

Currently, Mylan has 170 ANDAs pending FDA approval representing $97.8 billion in annual sales, according to IMS Health. Forty-six of these pending ANDAs are potential first-to-file opportunities, representing $24.3 billion in annual brand sales, for the 12 months ending June 30, 2010, according to IMS Health.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 140 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information, please visit www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Matrixx Initiatives, Inc. Announces End of Go-Shop Period
2. Matrixx Initiatives, Inc. Summarizes Ongoing Go-Shop Process and Board Reaffirms Recommendation
3. Matrixx Initiatives, Inc. Reports Fiscal 2011 Third Quarter Net Sales of $20.3 Million and Net Loss of $11.3 Million, or $(1.21) Per Share
4. Mylans Matrix Receives Tentative FDA Approval Under PEPFAR for Lamivudine and Zidovudine Tablets, 30 mg/60 mg
5. Matrixx Initiatives, Inc. and H.I.G. Capital Announce Early Termination of HSR Waiting Period
6. First Patient Enrolled in Multi-Center Clinical Trial of the CorMatrix® ECM® for Pericardial Closure to Reduce the Incidence of New Onset Postoperative Atrial Fibrillation
7. SRI International and PhenoMatriX Collaborate to Develop Platin-Based Chemotherapies
8. National University Hospital Singapore Operates on Asias 1st TRAM Flap Patient Using TIGR® Matrix Surgical Mesh, the Worlds 1st Long-Term Resorbable Mesh
9. Collagen Matrix, Inc. Expands Operations and Moves Corporate Headquarters to Oakland, New Jersey
10. Matrixx Initiatives, Inc. Sets Time for Discussion of Fiscal 2011 Second Quarter Financial Results
11. National University Hospital Singapore Receives DSRB Approval to Use TIGR® Matrix Surgical Mesh in a New Randomized Controlled TRAM Flap Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... ... Research and Markets has announced the addition of the ... their offering. The global active pharmaceutical ingredients (API) ... by 2025. The rising prevalence of lifestyle-induced & age-related diseases and ... Advancements in recombinant molecular technologies and high capitalization for development of ...
(Date:2/28/2017)... Feb. 27, 2017  Titan Pharmaceuticals, Inc. (NASDAQ: ... treatment of select chronic diseases utilizing its ProNeura™ ... the U.S. Food & Drug Administration (FDA) has ... Investigational New Drug Application (IND) and has requested ... study pending submission of the requested information and ...
(Date:2/28/2017)... -- Medical robots market is projected to reach USD ... 2016, growing at a CAGR of 21.1% in the ... Read the full report: http://www.reportlinker.com/p04730562-summary/view-report.html ... advancements, increase in funding for medical robots research, issuance ... investments are the key factors driving the growth of ...
Breaking Medicine Technology:
(Date:2/28/2017)... ... , ... BrightStar Care Marietta announced that it has received the 2017 Best ... is granted only to top-ranking home care providers, based on client satisfaction scores gathered ... care providers from across the country who have proven their ability to provide the ...
(Date:2/27/2017)... ... February 27, 2017 , ... ... care industry, announces Chris Brandl as its New Guest Director. , Brandl ... to corporations throughout his career. He began his professional career at Omnium Worldwide, ...
(Date:2/27/2017)... Ohio (PRWEB) , ... February 27, 2017 , ... Elisa Guajardo Carothers is not your ... Life” to studying to become a nun. Now, she writes about God, when she isn’t ... “You Know BC and AD, Here is BS! (Before Satan),” she offers a comedic look ...
(Date:2/27/2017)... , ... February 27, 2017 , ... ... threshold mark last week. In addition, Discount Power's RCE (Residential Customer Equivalent) count ... in March 2014. The company had 800 customers and 2,250 RCEs at the ...
(Date:2/26/2017)... (PRWEB) , ... February 25, 2017 , ... The February ... Jong-un, heightened awareness and concern over nerve agents and the deadly use of chemical ... human nervous system and how even small doses can be lethal. , Jay Jagannathan, ...
Breaking Medicine News(10 mins):